Solopharm is a Russian pharmaceutical company producing medicines, medical devices and dietary supplements.

Company history

July 2011

Start of the plant construction and laying of the foundation

March 2013

Completion of the construction and a start of an office work

June 2014

Launch of the 1st stage. The first series of infusion solutions are released

July 2015

Launch of the 2nd stage. Production of ophthalmic and nasal products in multidose form

April 2017

Launch of the 3rd stage — 10 new lines. The GMP certificate is received

April 2019

Solopharm becomes the fastest growing company for the second year in a row. «Platinum Ounce», the prestigious pharmaceutical award is received

May 2019

ISO 13485:2016 certificate for the export of medical devices is received

April 2020

Solopharm received the status of a strategic enterprise in the Russian pharmaceutical industry

July 2020

Launch of the biotechnological developments’ laboratory

September 2020

Foundation for solid dosage forms plant is laid.
Solopharm is included in TOP-20 of pharmaceutical companies according to Forbes magazine

February 2021

Solopharm is in Top-10 of the most rapidly developing companies in retail segment by the end of 2020

July 2021

Solopharm receives the EAEU GMP Certificate

September 2021

Solopharm is ranked #16 on the Forbes’ 2021 list of best domestic drug manufacturers

January 2022

Solopharm launches a new manufacturing site for dietary supplements

April 2022

The plant for production of solid dosage forms is opened

June 2022

Confirmation of the Solopharm medical device quality management system to the ISO 13485: 2016 requirements

October 2022

Solopharm entered the TOP-10 in the «Made in St. Petersburg and Leningrad region» nomination, «Fontanka.ru - Recognition and Influence» award

December 2022

Solopharm is ranked №1 in terms of online sales growth rate (according to AlphaRM for 11M-2022)

April 2023

Launch of the 4th stage of the liquid dosage forms production. Increasing the manufacturing facilities of existing and new drugs production, incl. new release forms

April 2023

Launch of the 2nd stage of the dietary supplements plant. Production of dietary supplements in capsules

May 2023

Launch of the plant for design, production, and installation of clean rooms

June 2023

Groundbreaking of the plant for the production of biotechnological products

October 2023

Solopharm entered again the TOP-10 in the «Made in St. Petersburg and Leningrad region» and «Employer of the year» nominations, «Fontanka.ru - Recognition and Influence» awards

March 2024

Launch of the ESS pharmaceutical warehouse

November 2024

Solopharm entered the TOP-10 finalists of the Award «Fontanka.ru: Recognition and Influence» in the nomination «Made in St. Petersburg and Leningrad Region»

March 2025

Solopharm is ranked №8 in the Forbes ranking of the «20 best pharmaceutical manufacturers in Russia – 2025»

April 2025

Launch of the 2nd microbiological laboratory at E11 for quality control of solid dosage forms, soft dosage forms and dietary supplements plants

September 2025

Launch of the first site in Russia with two automated lines: for hyaluronic acid cross-linking and for drug product filling

November 2025

Solopharm is ranked among the Top 10 companies in the «Employer of the Year» and «Made in St. Petersburg and Leningrad Oblast» nominations of the «Fontanka.ru — Recognition and Influence» award

Solopharm received the status of a strategic enterprise in the Russian pharmaceutical industry (list of strategically important enterprises of the Russian Federation 2020)

Solopharm is in the Top 10 companies in the «Employer of the Year» and «Made in St. Petersburg & Leningrad Oblast» nominations of the «Fontanka.ru — Recognition and Influence» award (November 2025)

Angidak recognized as one of the successful brands with high growth in «Knowledge» and «Consumption» indicators (IPSOS, Mar. 2025)

Solopharm launched its podcast «S polzoi» (To Good Use)

Solopharm ranks 8th in the «Forbes — 2025: 20 Best Pharmaceutical Manufacturers in Russia» rating (Forbes, March 2025)

Diagistan was the №1 launch among April launches (IPSOS, Apr '25)

Gilan® Dex ranked in the Top 10 successful launches (IPSOS, Apr '25)

Gilan® Extra ranked in the Top 15 successful launches (IPSOS, MAT Apr 2025)

Ingasalin® and Trekrezan® are included in the list of recommendations from the Ministry of Health

Solopharm is in the Top 10 domestic manufacturers (according to Pharmvestnik, for the period of Aug '24 - July '25)

Solopharm launched the first site in Russia with two automated lines for hyaluronic acid cross-linking and drug product filling (September 2025)

Solosorb was the winner of the «Green Cross» award in the «Pharmacists Choice: Enterosorbents for Adults and Children» nomination (2025)

Atrevozol® was the winner of the «Green Cross» award in the «No. 1 Drug for Anxiety and Stress» nomination (2025)

Solopharm is in the Top 20 in the retail segment (CRPT, based on 9-month 2025 results, medicinal products only, sell-out)

Solopharm is in the Top 30 in the retail segment (IQVIA, based on 9-month 2025 results, medicinal products only, sell-in)

Solopharm ranked 2nd in the «Company — Leader of the Ophthalmic Market in Russia» nomination at the Russian Pharma Awards® 2025

Oleg Zherebtsov is in the Top 100 Most Influential People in Pharma and Medicine in the «Founders / Owners» category (Pharma & Medical Recruitment and SFE & Marketing Excellence Academy, 2025)

About Us